Skip to main content
Figure 2 | BMC Health Services Research

Figure 2

From: Proton pump inhibitors: potential cost reductions by applying prescribing guidelines

Figure 2

Estimated annual net ingredient cost savings (€ per 1000 claimants) for the 5 scenarios by age distribution of the HSE-PCRS population. Notes: Scenario 1 – Least expensive PPI at initiation. After 3 months of initial therapy: Scenario 2- Therapeutic switching (cheaper brand/generic equivalent), Scenario 3- Dose reduction (maintenance therapy), Scenario 4- Therapeutic switching and dose reduction and Scenario 5- Therapeutic substitution.

Back to article page